サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：中枢神経系治療薬の世界市場 (～2027年)：薬剤クラス・用途・投与経路・エンドユーザー・流通チャネル・地域別の競合・予測・機会
市場調査レポート
商品コード
1121072

中枢神経系治療薬の世界市場 (～2027年)：薬剤クラス・用途・投与経路・エンドユーザー・流通チャネル・地域別の競合・予測・機会

Global Central Nervous System Therapeutics Market By Drug Class By Application By Route of Administration By End Users By Distribution Channel By Region, Competition Forecast & Opportunities, 2027
出版日: | 発行: TechSci Research | ページ情報: 英文 113 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.85円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

中枢神経系治療薬の世界市場 (～2027年)：薬剤クラス・用途・投与経路・エンドユーザー・流通チャネル・地域別の競合・予測・機会
出版日: 2022年09月01日
発行: TechSci Research
ページ情報: 英文 113 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の中枢神経系治療薬の市場は、予測期間である2023年から2027年の間に強いCAGRで成長すると予想されています。

中枢神経系疾患の有病率の上昇や、中枢神経系疾患の治療・診断の進歩などの要因が同市場の需要を促進しています。また、政府当局、医療制度、非営利団体、市場関係者による神経障害に関する意識向上への取り組みも予測期間中の市場成長をさらに後押しすると期待されています。

当レポートでは、世界の中枢神経系治療薬の市場を調査し、市場概要、市場規模の推移・予測、各種区分・地域/主要国別の内訳、市場への各種影響因子の分析、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

目次

第1章 製品概要

第2章 調査手法

第3章 COVID-19：世界の中枢神経系治療薬市場に与える影響

第4章 エグゼクティブサマリー

第5章 VOC (顧客の声)

第6章 世界の中枢神経系治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 薬剤クラス別（鎮痛薬・麻酔薬・抗けいれん薬・抗てんかん薬・抗パーキンソン薬・その他）
    • 用途別（神経血管疾患・メンタルヘルスと外傷・神経変性疾患・感染症・中枢神経系癌・その他）
    • 投与経路別（経口・非経口・その他）
    • エンドユーザー別（病院・診療所・診断ラボ・その他）
    • 流通チャネル別（病院薬局・オンライン薬局・小売薬局）
    • 企業別
    • 地域別（北米・欧州・アジア太平洋・南米・中東&アフリカ）
  • 製品市場マップ

第7章 北米の中枢神経系治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 薬剤クラス別
    • 用途別
    • 投与経路別
    • エンドユーザー別
    • 流通チャネル別
    • 国別
  • 国別分析

第8章 欧州の中枢神経系治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 薬剤クラス別
    • 用途別
    • 投与経路別
    • エンドユーザー別
    • 流通チャネル別
    • 国別
  • 国別分析

第9章 アジア太平洋の中枢神経系治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 薬剤クラス別
    • 用途別
    • 投与経路別
    • エンドユーザー別
    • 流通チャネル別
    • 国別
  • 国別分析

第10章 中東およびアフリカの中枢神経系治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 薬剤クラス別
    • 用途別
    • 投与経路別
    • エンドユーザー別
    • 流通チャネル別
    • 国別
  • 国別分析

第11章 南米の中枢神経系治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 薬剤クラス別
    • 用途別
    • 投与経路別
    • エンドユーザー別
    • 流通チャネル別
    • 国別
  • 国別分析

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向・市場展開

第14章 競合情勢

  • 競合の見通し
  • 世界の企業プロファイル
    • Eli Lilly and Company Ltd.
    • Merck & Co. Inc.
    • AstraZeneca PLC
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche AG
    • Biogen Inc.
    • Pfizer Inc.
    • GlaxoSmithKline PLC
    • Otsuka Holdings Co. Ltd.
    • Johnson & Johnson Services Inc.
    • Sanofi SA
    • Bristol Myers Squibb Pharmaceuticals Ltd.
    • Bayer AG
    • Amgen Inc.

第15章 戦略的提言

第16章 当社について・免責事項

目次
Product Code: 7322

The global central nervous system therapeutics market is anticipated to grow at a strong CAGR during the forecast period, 2023-2027. Factors such as the rise in prevalence of central nervous system disorders and advancements in therapeutics and diagnostics of central nervous system disorders are driving the demand for the global central nervous system therapeutics market. Growing diagnosis rates in developed and emerging economies are presenting a large patient pool that requires treatment. Also, the initiatives by the government authorities, healthcare systems, non-profit organizations, and market players to create awareness about neurological disorders are further expected to support the growth of the global central nervous system therapeutics market in the forecast period.

The global central nervous system therapeutics market is segmented into drug class, application, route of administration, end user, distribution channels, regional distribution, and competitive landscape. Based on application, the market is fragmented into neurovascular diseases, mental health and trauma, neurodegenerative diseases, infectious diseases, cns cancer, and others. Neurodegenerative diseases are expected to capture the highest market share during the forecast period, 2023-2027. The high cost of treatment of neurodegenerative diseases and the increased prevalence of neurodegenerative diseases such as Parkinson's disease, multiple sclerosis, and Alzheimer's disease are driving the segment demand.

North America is expected to dominate the global central nervous system therapeutics market during the forecast period. The presence of key market players in the region and the initiatives taken by market players to develop new technologies are infleuncing the market demand. Also, the rising incidence of mental health conditions and neurological disorders is expected to propel the market demand in the forecast period.

The major market players operating in the global central nervous system therapeutics market are: Eli Lilly and Company Ltd., Merck & Co. Inc., AstraZeneca PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., GlaxoSmithKline PLC, Otsuka Holdings Co. Ltd., Johnson & Johnson Services Inc., Sanofi SA, Bristol Myers Squibb Pharmaceuticals Ltd., Bayer AG, Amgen Inc., among others.

Years considered for this report:

  • Historical Years: 2017 - 2020
  • Base Year: 2021
  • Estimated Year: 2022
  • Forecast Period: 2023 - 2027

Objective of the Study:

  • To analyze and forecast the market size of Global central nervous system therapeutics market from 2017 to 2021.
  • To estimate and forecast the market size of Global central nervous system therapeutics market from 2022 to 2027 and growth rate until 2027.
  • To classify and forecast global central nervous system therapeutics market based on drug class, application, route of administration, end user, distribution channel, and regional distribution.
  • To identify dominant region or segment in the global central nervous system therapeutics market.
  • To identify drivers and challenges for global central nervous system therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global central nervous system therapeutics market.
  • To identify and analyze the profile of leading players operating in global central nervous system therapeutics market.
  • To identify key sustainable strategies adopted by market players in global central nervous system therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of global central nervous system therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Central nervous system therapeutics manufacturers, end users, service providers and other stakeholders
  • Distributers and suppliers of central nervous system therapeutics and services and other stakeholders
  • Organizations, forums, and alliances related to central nervous system therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, Global central nervous system therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Market, By Drug Class:

  • Analgesics
  • Anesthetics
  • Anticonvulsants
  • Antiepileptics
  • Anti-Parkinson Agents
  • Others

Market, By Application:

  • Neurovascular Diseases
  • Mental Health and Trauma
  • Neurodegenerative Diseases
  • Infectious Diseases
  • CNS Cancer
  • Others

Market, By Route of Administrations:

  • Oral
  • Parenteral
  • Others

Market, By End User:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Others

Market, By Distribution Channel:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Market, By Region:

  • North America
  • APAC
  • Europe
  • MEA
  • South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global central nervous system therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Central Nervous System Therapeutics Market

4. Executive Summary

5. Voice of Customer

6. Global Central Nervous System Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Analgesics, Anesthetics, Anticonvulsants, Antiepileptics, Anti-Parkinson Agents, Others)
    • 6.2.2. By Application (Neurovascular Diseases, Mental Health and Trauma, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer, Others)
    • 6.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 6.2.4. By End Users (Hospitals, Clinics, Diagnostic Laboratories, Others)
    • 6.2.5. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
    • 6.2.6. By Company (2021)
    • 6.2.7. By Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)
  • 6.3. Product Market Map

7. North America Central Nervous System Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Application
    • 7.2.3. By Route of Administration
    • 7.2.4. By End Users
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country (United States; Canada; Mexico)
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Central Nervous System Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By End Users
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Canada Central Nervous System Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By End Users
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. Mexico Central Nervous System Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By End Users
        • 7.3.3.2.5. By Distribution Channel

8. Europe Central Nervous System Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Application
    • 8.2.3. By Route of Administration
    • 8.2.4. By End Users
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country (France; Germany; UK; Italy; Spain)
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Central Nervous System Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By End Users
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. Germany Central Nervous System Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By End Users
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. United Kingdom Central Nervous System Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By End Users
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. Italy Central Nervous System Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By End Users
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Spain Central Nervous System Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By End Users
        • 8.3.5.2.5. By Distribution Channel

9. Asia-Pacific Central Nervous System Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Application
    • 9.2.3. By Route of Administration
    • 9.2.4. By End Users
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country (China; India; Japan; South Korea; Australia)
  • 8.3 Asia-Pacific: Country Analysis
    • 8.3.1 China Central Nervous System Therapeutics Market Outlook
      • 8.3.1.1 Market Size & Forecast
        • 8.3.1.1.1 By Value
      • 8.3.1.2 Market Share & Forecast
        • 8.3.1.2.1 By Drug Class
        • 8.3.1.2.2 By Application
        • 8.3.1.2.3 By Route of Administration
        • 8.3.1.2.4 By End Users
        • 8.3.1.2.5 By Distribution Channel
    • 8.3.2 India Central Nervous System Therapeutics Market Outlook
      • 8.3.2.1 Market Size & Forecast
        • 8.3.2.1.1 By Value
      • 8.3.2.2 Market Share & Forecast
        • 8.3.2.2.1 By Drug Class
        • 8.3.2.2.2 By Application
        • 8.3.2.2.3 By Route of Administration
        • 8.3.2.2.4 By End Users
        • 8.3.2.2.5 By Distribution Channel
    • 8.3.3 Japan Central Nervous System Therapeutics Market Outlook
      • 8.3.3.1 Market Size & Forecast
        • 8.3.3.1.1 By Value
      • 8.3.3.2 Market Share & Forecast
        • 8.3.3.2.1 By Drug Class
        • 8.3.3.2.2 By Application
        • 8.3.3.2.3 By Route of Administration
        • 8.3.3.2.4 By End Users
        • 8.3.3.2.5 By Distribution Channel
    • 8.3.4 South Korea Central Nervous System Therapeutics Market Outlook
      • 8.3.4.1 Market Size & Forecast
        • 8.3.4.1.1 By Value
      • 8.3.4.2 Market Share & Forecast
        • 8.3.4.2.1 By Drug Class
        • 8.3.4.2.2 By Application
        • 8.3.4.2.3 By Route of Administration
        • 8.3.4.2.4 By End Users
        • 8.3.4.2.5 By Distribution Channel
    • 8.3.5 Australia Central Nervous System Therapeutics Market Outlook
      • 8.3.5.1 Market Size & Forecast
        • 8.3.5.1.1 By Value
      • 8.3.5.2 Market Share & Forecast
        • 8.3.5.2.1 By Drug Class
        • 8.3.5.2.2 By Application
        • 8.3.5.2.3 By Route of Administration
        • 8.3.5.2.4 By End Users
        • 8.3.5.2.5 By Distribution Channel

10. Middle East and Africa Central Nervous System Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Application
    • 10.2.3. By Route of Administration
    • 10.2.4. By End Users
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country (UAE; Saudi Arabia; South Africa)
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Central Nervous System Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By End Users
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Saudi Arabia Central Nervous System Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By End Users
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. UAE Central Nervous System Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By End Users
        • 10.3.3.2.5. By Distribution Channel

11. South America Central Nervous System Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Application
    • 11.2.3. By Route of Administration
    • 11.2.4. By End Users
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country (Brazil; Argentina; Colombia)
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Central Nervous System Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Application
        • 11.3.1.2.3. By Route of Administration
        • 11.3.1.2.4. By End Users
        • 11.3.1.2.5. By Distribution Channel
    • 11.3.2. Argentina Central Nervous System Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Application
        • 11.3.2.2.3. By Route of Administration
        • 11.3.2.2.4. By End Users
        • 11.3.2.2.5. By Distribution Channel
    • 11.3.3. Colombia Central Nervous System Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Drug Class
        • 11.3.3.2.3. By Application
        • 11.3.3.2.4. By Route of Administration
        • 11.3.3.2.5. By End Users
        • 11.3.3.2.6. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Global Players Profiled (Leading Companies)
    • 14.2.1. Eli Lilly and Company Ltd.
    • 14.2.2. Merck & Co. Inc.
    • 14.2.3. AstraZeneca PLC
    • 14.2.4. Novartis AG
    • 14.2.5. Teva Pharmaceutical Industries Ltd.
    • 14.2.6. F. Hoffmann-La Roche AG
    • 14.2.7. Biogen Inc.
    • 14.2.8. Pfizer Inc.
    • 14.2.9. GlaxoSmithKline PLC
    • 14.2.10. Otsuka Holdings Co. Ltd.
    • 14.2.11. Johnson & Johnson Services Inc.
    • 14.2.12. Sanofi SA
    • 14.2.13. Bristol Myers Squibb Pharmaceuticals Ltd.
    • 14.2.14. Bayer AG
    • 14.2.15. Amgen Inc.

15. Strategic Recommendations

16. About Us & Disclaimer